Notable Labs

Notable Labs FCF/Debt

The Free Cash Flow to Debt Ratio of Notable Labs (NTBLQ) as of Nov 17, 2026 is -4,041.35 %. In the previous year, Free Cash Flow to Debt Ratio was -21,300.00 % — a change of -81.03% (higher).

FCF/Debt

-4,041.35 %

YoY

-81.03%

Last updated:

Free Cash Flow to Debt Ratio of Notable Labs is 2023 -4,041.35 % . Free Cash Flow to Debt Ratio of Notable Labs was 2022 -21,300.00 % . It decreases by -81.03% higher compared to the previous year.

The Notable Labs FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-2,238.75 USD
Jan 1, 2019
-2,685.71 USD
Jan 1, 2020
-21,300.00 USD
Jan 1, 2023
-4,041.35 USD
The Notable Labs FCF/Debt history
YEARFCF/DebtYoY
-4,041.35 %-81.03%
-21,300.00 %+693.09%
-2,685.71 %+19.96%
-2,238.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Free Cash Flow to Debt Ratio of Notable Labs is -4,041.35 % in 2023.

Free Cash Flow to Debt Ratio of Notable Labs changed from -21,300.00 % to -4,041.35 %, representing a -81.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Notable Labs since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Notable Labs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Notable Labs

All Key Metrics — Notable Labs